Role of Blood-Brain Barrier in Alzheimer’s Disease
The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
The blood-brain barrier (BBB) is involved in the pathogenesis of Alzheimer's disease (AD). BBB is a highly selective semipermeable structural and chemical barrier which ensures a stable internal environment of the brain and prevents foreign objects invading the brain tissue. BBB dysfunction induces the failure of Aβ transport from brain to the peripheral circulation across the BBB. Especially, decreased levels of LRP-1 (low density lipoprotein receptor-related protein 1) and increased levels of RAGE (receptor for advanced glycation endproducts) at the BBB can cause the failure of Aβ transport. The pathogenesis of AD is related to the BBB structural components, including pericytes, astrocytes, vascular endothelial cells, and tight junctions. BBB dysfunction will trigger neuroinflammation and oxidative stress, then enhance the activity of β-secretase and γ-secretase, and finally promote Aβ generation. A progressive accumulation of Aβ in brain and BBB dysfunction may become a feedback loop that gives rise to cognitive impairment and the onset of dementia. The correlation between BBB dysfunction and tau pathology has been well-reported. Therefore, regulating BBB function may be a new therapeutic target for treating AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661 · cited 2×
“TheBBBhasthemostimpor-tantroleinmaintainingbrainfunctionamongthe threebrainbarriers[14,15].”
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Establishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670 · cited 1×
“Pericytes, an important component of neurovascular unit and BBB, act like the gatekeepers of the BBB, and exquisitely regulate the movement of brain cellsandthetransportationofnutrientsandmoleculesbetweenthebloodandthebraininterstitialfluidthatsurroundsthebraincells [87–89].”
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier
Huber, J. D., Egleton, R. D., & Davis, T. P. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02004-x · Cited by 786 · cited 1×
“…or progression of numerous brain diseases, such as hemorrhagic and ischemic stroke, intracranial infectious diseases, intracranial autoimmune diseases, epilepsy, lupus cerebritis, and brain tumors [105, 106], as well as neurodegenerative diseases like Parkinson’s disease and AD [45, 107].”
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767 · cited 7×
“Second,A (cid:2) pathology suffering from BBB dysfunction can indirectly facilitate the onset of tau pathology, representing a mechanistic link between A (cid:2) /tau deposition after BBB dysfunction [1, 126].”
InfluentialAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · cited 2×
“528 Yet, the role of BBB in the pathogenesis of AD is 529 still a challenge [12, 132].”
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670
Halliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.44 · Cited by 649
Research works printed but not linked: 1
- Volpina, 2015, [Fragment of receptor for advanced glycation end products improves memory state in a model of Alzheimer’s disease, Bioorg Khim, 41, 709
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
“The presence of BBB avoids the brain from damage by keeping a stable environment.(28,29) But it also limits the drugs that enter into the CNS for treating brain diseases such as neurodegenerative diseases and brain cancer.”
BackgroundHan, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
Więckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M., & Wojda, U. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101397 · Cited by 343
“…the molecular mechanisms responsible for BBB function and much attention has been paid to BBB deterioration in neurological diseases including AD, as extensively reviewed (Cai et al., 2018; Costea et al., 2019; Profaci et al., 2020; Sweeney et al., 2018, 2019b; Yamazaki and Kanekiyo, 2017).”
Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R. N., Bild, V., Beschea Chiriac, S. I., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 297
Magnetic iron oxide nanoparticles for brain imaging and drug delivery
Qiao, R., Fu, C., Forgham, H., Javed, I., Huang, X., Zhu, J., Whittaker, A. K., & Davis, T. P. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114822 · Cited by 245
Neurovascular Unit Dysfunction and Neurodegenerative Disorders
Yu, X., Ji, C., & Shao, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00334 · Cited by 244
Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview
Archie, S. R., Al Shoyaib, A., & Cucullo, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111779 · Cited by 220
“However, various studies have also demonstrated that BBB dysfunction plays a crucial role in generating Aβ [195–197] by activating β-secretase and γ-secretase [196,198].”
BackgroundExtracellular Vesicles as Signaling Mediators and Disease Biomarkers across Biological Barriers
Simeone, P., Bologna, G., Lanuti, P., Pierdomenico, L., Guagnano, M. T., Pieragostino, D., Del Boccio, P., Vergara, D., Marchisio, M., Miscia, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072514 · Cited by 214
The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease
Vecchio, I., Sorrentino, L., Paoletti, A., Marra, R., & Arbitrio, M. (2021) · Journal of Central Nervous System Disease · doi:10.1177/11795735211029113 · Cited by 178
Tau Protein and Its Role in Blood–Brain Barrier Dysfunction
Michalicova, A., Majerova, P., & Kovac, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.570045 · Cited by 177
Ferrari, E., Palma, C., Vesentini, S., Occhetta, P., & Rasponi, M. (2020) · Biosensors · doi:10.3390/bios10090110 · Cited by 172
In vitro modeling of the neurovascular unit: advances in the field
Bhalerao, A., Sivandzade, F., Archie, S. R., Chowdhury, E. A., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00183-7 · Cited by 147
The Neurovascular Unit Dysfunction in Alzheimer’s Disease
Soto-Rojas, L. O., Pacheco-Herrero, M., Martínez-Gómez, P. A., Campa-Córdoba, B. B., Apátiga-Pérez, R., Villegas-Rojas, M. M., Harrington, C. R., de la Cruz, F., Garcés-Ramírez, L., & Luna-Muñoz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042022 · Cited by 136
“This neuroinflammatory environment could promote BBB damage and accelerate the development of tau phosphorylation and NFT formation (Figure 2b) [57].”
BackgroundGong, T., Chen, Q., Mao, H., Zhang, Y., Ren, H., Xu, M., Chen, H., & Yang, D. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.925435 · Cited by 138
“correlation between BBB dysfunction and tau pathology is reported (Cai et al., 2018).”
BackgroundMast Cells in Stress, Pain, Blood-Brain Barrier, Neuroinflammation and Alzheimer’s Disease
Kempuraj, D., Mentor, S., Thangavel, R., Ahmed, M. E., Selvakumar, G. P., Raikwar, S. P., Dubova, I., Zaheer, S., Iyer, S. S., & Zaheer, A. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00054 · Cited by 136
“BBB dysfunction can activate β and γ secretase and generate and increase Aβ level in AD (Cai et al., 2018).”
BackgroundPathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives
Fisher, R. A., Miners, J. S., & Love, S. (2022) · Brain Pathology · doi:10.1111/bpa.13061 · Cited by 131
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
“BBB dysfunction is directly correlated with amyloid and tau pathology in AD [8].”
BackgroundRevolutionizing Neurocare: Biomimetic Nanodelivery Via Cell Membranes
Liao, J., Gong, L., Xu, Q., Wang, J., Yang, Y., Zhang, S., Dong, J., Lin, K., Liang, Z., Sun, Y., et al. (2024) · Advanced Materials · doi:10.1002/adma.202402445 · Cited by 138
Breaking the Barrier: The Role of Proinflammatory Cytokines in BBB Dysfunction
Gryka-Marton, M., Grabowska, A. D., & Szukiewicz, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083532 · Cited by 153
Beltrán-Velasco, A. I., & Clemente‐Suárez, V. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062440 · Cited by 137
“Additionally, chronic peripheral inflammation in Alzheimer’s disease further compromises BBB function, allowing increased immune cell infiltration and exacerbating neuroinflammation in these key regions [68,69].”
Wang, X., Yu, J., Sun, Y., Wang, H., Shan, H., & Wang, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107725 · Cited by 116
Alzheimer's disease pathophysiology in the Retina
Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 111
Recent Progress in Microfluidic Models of the Blood-Brain Barrier
Jiang, L., Li, S., Zheng, J., Li, Y., & Huang, H. (2019) · Micromachines · doi:10.3390/mi10060375 · Cited by 96
“The blood-brain barrier (BBB) is a highly selective barrier that regulates passive and active transport between the brain parenchyma and peripheral blood [1,2].”
BackgroundRetinal Vasculopathy in Alzheimer’s Disease
Shi, H., Koronyo, Y., Rentsendorj, A., Fuchs, D.-T. S., Sheyn, J., Black, K. L., Mirzaei, N., & Koronyo‐Hamaoui, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.731614 · Cited by 94
The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease
Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91
“Substantial evidence shows that the BBB pathway is of crucial importance for rapid removal of Aβ from the brain (Cai et al., 2018, Hladky and Barrand, 2018, Cheng and Haorah, 2019).”
BackgroundCircadian rhythms in the blood–brain barrier: impact on neurological disorders and stress responses
Schurhoff, N. A., & Toborek, M. J. (2023) · Molecular Brain · doi:10.1186/s13041-023-00997-0 · Cited by 100
Yang, J., Liang, J., Hu, N., He, N., Liu, B., Liu, G., & Qin, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70091 · Cited by 120
“(iii) The integrity of the BBB is crucial in AD progression, and its compromised state incites inflammatory and neurodegenerative processes [19, 20].”
BackgroundViral Involvement in Alzheimer’s Disease
Sait, A., Angeli, C., Doig, A. J., & Day, P. J. R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00719 · Cited by 85
Li, J., Wei, Y., Zhang, C., Bi, R., Qiu, Y., Li, Y., & Hu, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020621 · Cited by 85
“Although the BBB is damaged in various pathological, ND conditions, such as ischemic stroke (IS) [11], traumatic brain injury (TBI) [12], multiple sclerosis (MS) [13], glioblastoma multiforme (GBM) [14], Parkinson’s disease (PD) [15], and Alzheimer ‘s disease (AD) [16], it is also a significant challenge for the accum…”
BackgroundFerroptosis and Iron Homeostasis: Molecular Mechanisms and Neurodegenerative Disease Implications
Abdukarimov, N., Kokabi, K., & Kunz, J. (2025) · Antioxidants · doi:10.3390/antiox14050527 · Cited by 112
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
“metabolism, including transport and clearance (for detailed reviews, see (Cai et al., 2018; Erickson and Banks, 2013).”
BackgroundInfluentialBasal lamina changes in neurodegenerative disorders
Nguyen, B., Bix, G., & Yao, Y. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00502-y · Cited by 75
“Accumulating evidence suggests that tau pathology is also correlated with BBB dysfunction [258].”
BackgroundYuan, S., Yang, J., Jian, Y., Lei, Y., Yao, S., Hu, Z., Liu, X., Tang, C., & Liu, W. (2022) · Nutrients · doi:10.3390/nu14194134 · Cited by 79
“[83] noted that astrocyte dysfunction can easily impair the normal physiological function of the BBB and induce an imbalance in the clearance of Aβ from the brain parenchyma to the blood.”
BackgroundGadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 68
“Additionally, it causes failure of Aβ transport from brain to periphery due to decreased levels of LRP‐1 and increased levels of RAGE at the BBB, which consequently gives rise to cognitive impairment.(411) Aβ putative receptor at BBB controls the level of soluble isoforms of Aβ in the brain by influx of circulating Aβ…”
BackgroundWiȩckowska-Gacek, A., Mietelska-Porowska, A., Chutorański, D., Wydrych, M., Długosz, J., & Wojda, U. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.654509 · Cited by 71
Materials for blood brain barrier modeling in vitro
Ferro, M. P., Heilshorn, S. C., & Owens, R. M. (2020) · Materials Science and Engineering R Reports · doi:10.1016/j.mser.2019.100522 · Cited by 75
An, L., Shen, Y., Chopp, M., Zacharek, A., Venkat, P., Chen, Z., Li, W., Yu, Q., Landschoot‐Ward, J., & Chen, J. (2021) · Aging and Disease · doi:10.14336/ad.2020.0523 · Cited by 67
RAGE Inhibitors in Neurodegenerative Diseases
Reddy, V. P., Aryal, P., & Soni, P. (2023) · Biomedicines · doi:10.3390/biomedicines11041131 · Cited by 76
“Disruption of the blood–brain barrier (BBB), consisting predominantly of endothelial cells, is one of the risk factors in the onset of AD and thus AGE–RAGE interactions have also impacted on the integrity of the BBB [52].”
BackgroundNon-Coding RNAs as Novel Regulators of Neuroinflammation in Alzheimer’s Disease
Liu, Y., Cheng, X. M., Li, H., Hui, S., Zhang, Z., Yang, X. J., & Peng, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908076 · Cited by 71
“When the BBB is disrupted, pro-inflammatory molecules are more prone to contact nerve tissues, causing synaptic damage and neuronal death (24, 25).”
BackgroundRoles and Mechanisms of Axon-Guidance Molecules in Alzheimer’s Disease
Zhang, L., Qi, Z., Li, J., Li, M., Du, X., Wang, S., Zhou, G., Xu, B., Liu, W., Xi, S., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02311-2 · Cited by 64
Liang, X., Fa, W., Wang, N., Peng, Y., Liu, C., Zhu, M., Tian, N., Wang, Y., Han, X., Qiu, C., et al. (2022) · Aging Cell · doi:10.1111/acel.13748 · Cited by 65
Liu, S., Gao, J., Liu, K., & Zhang, H. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111560 · Cited by 61
Wu, M., Zhai, Y., Liang, X., Chen, W., Lin, R., Ma, L., Huang, Y., Zhao, D., Liang, Y., Zhao, W., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.842814 · Cited by 66
Gonzales‐Aloy, E., Ahmed-Cox, A., Tsoli, M., Ziegler, D. S., & Kavallaris, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114777 · Cited by 61
Ajikumar, A., Long, M. B., Heath, P. R., Wharton, S. B., Ince, P. G., Ridger, V. C., & Simpson, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205227 · Cited by 60
Impact of intestinal disorders on central and peripheral nervous system diseases
El-Hakim, Y., Bake, S., Mani, K. K., & Sohrabji, F. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105627 · Cited by 69
“Blood brain barrier dysfunction contributes to the onset and progression of AD (Kalaria, 2002; Deane and Zlokovic, 2007; Cai et al., 2018), as indicated by”
Recent advances in understanding the mechanisms of PM2.5-mediated neurodegenerative diseases
Zhu, X., Ji, X., Shou, Y., Huang, Y., Hu, Y., & Wang, H. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.04.017 · Cited by 56
Chen, Z., Wang, X., Du, S., Liu, Q., Xu, Z., Guo, Y., & Lin, X. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00900-6 · Cited by 66
“…studies have shown that malabsorption, rapid metabolism and systemic elimination, inefficient drug delivery systems, and selective permeability across the BBB [202] are also serious problems, which largely limit the bioavailability and neuroprotective effects of TCM in neurodegenerative diseases.”
BackgroundMechanistic new insights of flavonols on neurodegenerative diseases
Tahir, M. S., Almezgagi, M., Zhang, Y., Bashir, A., Abdullah, H. M., Gamah, M., Wang, X., Zhu, Q., Shen, X., Ma, Q., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111253 · Cited by 59
Targeting Alzheimer’s Disease: The Critical Crosstalk between the Liver and Brain
Huang, Z., Lin, H. W. (., Zhang, Q., & Zong, X. (2022) · Nutrients · doi:10.3390/nu14204298 · Cited by 50
“LRP-1 is an endocytic and signaling receptor expressed in multiple tissues, including LRP-1 existing on the cell surface and soluble form of LRP1 (sLRP1) in plasma [59,85].”
BackgroundXu, T., Lu, X., Peng, D., Wang, G., Chen, C., Liu, W., Wu, W., & Mason, T. J. (2019) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2019.104955 · Cited by 52
Blood-brain barrier integrity is the primary target of alcohol abuse
Wei, J., Dai, Y., Wen, W., Li, J., Ye, L. L., Xu, S., & Duan, D. D. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109400 · Cited by 58
MRI-Visible Perivascular Spaces and Risk of Incident Dementia: The Framingham Heart Study
Romero, J. R., Pinheiro, A., Aparicio, H. J., DeCarli, C. S., Demissie, S., & Seshadri, S. S. (2022) · Neurology · doi:10.1212/wnl.0000000000201293 · Cited by 49
“Men 664 (46) 214 (52) 317 (47) 102 (36) 31 (42) 321 (49) 275 (44) 62 (39) 6 (38)”
Drugs Modulating CD4+ T Cells Blood–Brain Barrier Interaction in Alzheimer’s Disease
Kubick, N., Flournoy, P. C. H., Enciu, A., Mickael, M., & Manda, G. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090880 · Cited by 50
“Data also suggest that depletion of hippocampal T cells infiltration in tau-driven AD mouse models decreased spatial cognitive impairments [8].”
BackgroundScieszka, D. P., Hunter, R., Begay, J., Bitsui, M., Lin, Y., Galewsky, J., Morishita, M., Klaver, Z. M., Wagner, J. G., Harkema, J. R., et al. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab147 · Cited by 54
Weng, S., Lai, Q.-L., Wang, J., Zhuang, L., Cheng, L., Mo, Y., Liu, L., Zhao, Z., Zhang, Y., & Qiao, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.899944 · Cited by 47
Purinergic signaling: A gatekeeper of blood-brain barrier permeation
Wang, Y., Zhu, Y., Wang, J., Dong, L., Liu, S., Li, S., & Wu, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1112758 · Cited by 58
Correia, A. S., Cardoso, A., & Vale, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168525 · Cited by 50
“This BBB dysfunction causes decreased Aβ entry from the brain to blood circulation, leading to its accumulation [48].”
BackgroundLv, X., Zhang, M., Cheng, Z., Wang, Q., Wang, P., Xie, Q., Ni, M., Shen, Y., Tang, Q., & Gao, F. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01199-5 · Cited by 47
Emerging nanotechnology for Alzheimer's disease: From detection to treatment
Song, N., Sun, S., Chen, K., Wang, Y., Wang, H., Meng, J., Guo, M., Zhang, X.-D., & Zhang, R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.004 · Cited by 44
IL-17A promotes the progression of Alzheimer’s disease in APP/PS1 mice
Cao, M., Liu, J., Zhang, X., Wang, Y., Hou, Y., Song, Q., Cui, Y., Zhao, Y., & Wang, P. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00397-x · Cited by 54
“Although the brain was once perceived as an immune-privileged area, researchers have observed the breakdown of the BBB in AD patients [25].”
BackgroundZhou, R., Chen, L.-L., Yang, H., Li, L., Liu, J., Chen, L., Hong, W.-J., Wang, C.-G., Ma, J.-J., Huang, J., et al. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210906092940 · Cited by 43
Zebhauser, P. T., Berthele, A., Goldhardt, O., Diehl‐Schmid, J., Priller, J., Ortner, M., & Grimmer, T. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01004-9 · Cited by 49
“CSF for peptide concentrations (t-Tau, Aβ42) was centrifuged at 2000×g and 4°C for 10 min, and aliquots were stored at – 80 °C. Peptide concentrations were analyzed with commercially available enzyme-linked immunosorbent assays (ELISA; INNOTEST hTAU Ag, Fujirebio Europe N.V.; IBL International GmbH; Amyloid-Beta [1-42…”
BackgroundMethodInfluentialsiRNA drug delivery across the blood–brain barrier in Alzheimer's disease
Sajid, M. I., Sheikh, F. S., Anis, F., Nasim, N., Sumbria, R. K., Nauli, S. M., & Tiwari, R. K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114968 · Cited by 59
Bhargavan, B., Woollard, S. M., Mcmillan, J. E. M., & Kanmogne, G. D. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00500-0 · Cited by 46
“[12, 14, 160] and AD [159, 161, 162] are associated with increased BBB injury as well as impairment in BBB tight-”
BackgroundThe Emerging Role of Circular RNAs in Alzheimer’s Disease and Parkinson’s Disease
Zhang, M., & Bian, Z. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.691512 · Cited by 47
“, 2016), blood-brain barrier (BBB) damage (Cai et al., 2018), neuroinflammatory response (Heppner et al.”
BackgroundGenetic networks in Parkinson’s and Alzheimer’s disease
Kelly, J., Moyeed, R. A., Carroll, C., Luo, S., & Li, X. (2020) · Aging · doi:10.18632/aging.102943 · Cited by 45
“In AD animal models circulating leukocytes have been shown to cross a dysfunctional blood brain barrier and impact brain integrity [54].”
Afsar, A., Castro, M. D. C. C., Soladogun, A. S., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087258 · Cited by 49
“BBB dysfunction can also induce tau hyperphosphorylation, and tau pathology can trigger BBB damage [5,144,149,150].”
BackgroundInfluentialAmyloid β oligomer induces cerebral vasculopathy via pericyte-mediated endothelial dysfunction
Chen, S., Guo, D., Zhu, Y., Xiao, S., Xie, J., Zhang, Z., Hu, Y., Huang, J., Ma, X., Ning, Z., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01423-w · Cited by 46
“On the other hand, when the structure of BBB is destroyed, the transport and degradation of Aβ decline, thus enhancing Aβ abnormal accumulation and forming a negative feedback loop [12, 13].”
BackgroundA review on α-mangostin as a potential multi-target-directed ligand for Alzheimer's disease
Yang, A., Liu, C., Wu, J., Kou, X., & Shen, R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173950 · Cited by 42
Panitch, R., Hu, J., Xia, W., Bennett, D. A., Stein, T. D., Farrer, L. A., & Jun, G. R. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00975-z · Cited by 39
“Dysfunction of the BBB, a semi-permeable border separating the extracellular fluid and brain tissue from circulating blood, has been implicated in the accumulation of amyloid-β (Aβ) and hyperphosphorylation of tau protein [7, 8].”
BackgroundCellular transcriptional alterations of peripheral blood in Alzheimer’s disease
Song, L., Yang, Y., Guo, Q., & Zhao, X. (2022) · BMC Medicine · doi:10.1186/s12916-022-02472-4 · Cited by 43
Claudin-5 and occludin levels in patients with psychiatric disorders − A systematic review
Maridaki, Z., Syrros, G., Delichatsiou, S. G., Warsh, J. J., & Konstantinou, G. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.11.006 · Cited by 46
“The crucial role of BBB dysfunction in various conditions has been highlighted in several studies over the last years (Cai et al., 2018; Thrippleton et al., 2019; Yang et al., 2019).”
BackgroundLin, X., Wen, X., Wei, Z., Guo, K., Shi, F., Huang, T., Wang, W., & Zheng, J. (2021) · Neuroreport · doi:10.1097/wnr.0000000000001599 · Cited by 39
Zhang, B., Lian, W., Zhao, J., Wang, Z., Liu, A., & Du, G. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6521146 · Cited by 56
“Astrocytic dysfunction could easily damage the normal physiological function of BBB, inducing the imbalance of Aβ clearance from the brain parenchyma into the blood [17].”
BackgroundLanz, M., Janeiro, M. H., Milagro, F. I., Puerta, E., Ludwig, I. A., Pineda-Lucena, A., Ramírez, M. J., & Solas, M. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111668 · Cited by 39
Mechanisms Involved in Epileptogenesis in Alzheimer’s Disease and Their Therapeutic Implications
Altuna, M., Olmedo‐Saura, G., Carmona‐Iragui, M., & Fortea, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084307 · Cited by 44
“This excitatory–inhibitory disbalance could increase the probability of the existence of interictal epileptiform activity and also of clinical and/or electrical epileptic seizures [102,103].”
BackgroundPeixoto-Rodrigues, M. C., Monteiro-Neto, J. R., Téglás, T., Toborek, M. J., Quinete, N., Hauser‐Davis, R. A., & Adesse, D. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.136832 · Cited by 41
“…or decreased expression of TJ proteins results in BBB disruption [100], which is critical to the initiation and perpetuation of neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease [117], amyotrophic lateral sclerosis (ALS) [118], ASD [119] and Parkinson’s disease [120].”
Brain Endothelial Cells in Blood–Brain Barrier Regulation and Neurological Therapy
Xiang, Y., Gu, Q., & Liu, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125843 · Cited by 49
“At the molecular level, AD brains exhibit reduced nuclear localization of β -catenin, leading to decreased expression of its downstream neuroprotective target genes [72,73].”
Impact of Gut Microbiome Manipulation in 5xFAD Mice on Alzheimer’s Disease-Like Pathology
Guilherme, M. D. S., Nguyen, V. T. T., Reinhardt, C., & Endres, K. (2021) · Microorganisms · doi:10.3390/microorganisms9040815 · Cited by 41
Copper neurotoxicity: Induction of cognitive dysfunction: A review
Feng, D., Zhao, Y., Li, W., Li, X., Wan, J., & Wang, F. (2023) · Medicine · doi:10.1097/md.0000000000036375 · Cited by 38
“[38] BBB disruption in elderly patients is associated with more rapid cognitive decline.”
BackgroundPhotobiomodulation Mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP
Miguel, M. S., Martin, K. L., Stone, J., & Johnstone, D. M. (2019) · Biomolecules · doi:10.3390/biom9100564 · Cited by 37
“As a response to disrupted blood perfusion and rising Aβ levels, tau protein accumulates and further obstructs the vessels, increasing the damage [67].”
BackgroundLi, C., Talukder, M., Xu, Y.-R., Zhu, S.-Y., Zhao, Y.-X., & Li, J. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.121400 · Cited by 39
de Kort, A. M., Kuiperij, H. B., Kersten, I., Versleijen, A. A. M., Schreuder, F. H. B. M., Nostrand, W. E. V., Greenberg, S. M., Klijn, C. J. M., Claassen, J. A. H. R., & Verbeek, M. M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12506 · Cited by 36
Macrophages and the development and progression of non-alcoholic fatty liver disease
Alabdulaali, B., Al‐Rashed, F., Al‐Onaizi, M., Kandari, A., Razafiarison, J., Tonui, D., Williams, M. R., Blériot, C., Ahmad, R., & Alzaïd, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1195699 · Cited by 39
“Moreover, mice fed a Western diet exhibit impairments in the blood-brain-barrier (BBB), which has been shown to trigger oxidative stress, leading to enhanced activity of b-secretase and g-secretase, which promote the generation of Ab peptides (9, 162).”
BackgroundReduced neurogenesis in human hippocampus with Alzheimer's disease
Cao, Y., Liu, P., Bian, H., Jin, S., Liu, J., Yu, N., Cui, H., Sun, F., Qian, X., Qiu, W., et al. (2023) · Brain Pathology · doi:10.1111/bpa.13225 · Cited by 43
“These astrocytes might penetrate A β plaques aiding in their separation from the surrounding neural fiber network and engulfing them [44, 45].”
BackgroundRole of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier
Cazalla, E., Cuadrado, A., & García‐Yagüe, Á. J. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00599-5 · Cited by 41
The Beneficial Role of Exercise on Treating Alzheimer’s Disease by Inhibiting β-Amyloid Peptide
Tan, Z., Dong, F., Wu, L., Feng, Y.-S., & Zhang, F. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02514-7 · Cited by 40
“The BBB is a highly specific chemical barrier with a semipermeable structure that isolates the brain from circulating blood and extracellular fluids [134, 135].”
BackgroundNew RNA-Based Breakthroughs in Alzheimer’s Disease Diagnosis and Therapeutics
Riscado, M., Baptista, B., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091397 · Cited by 35
“Consequently, neuroinflammatory responses will happen, which further contribute to neurodegeneration, taking place in a feed-forward loop [37,40,41].”
BackgroundAnti-Neuroinflammatory Potential of Natural Products in the Treatment of Alzheimer’s Disease
Deng, M., Yan, W., Gu, Z., Li, Y., Chen, L., & He, B. (2023) · Molecules · doi:10.3390/molecules28031486 · Cited by 42
“BBB dysfunction affects Aβ clearance and endothelial cell transport by inducing peripheral immune cells such as neutrophils, monocytes and others to enter the brain and then release inflammatory cytokines to activate glial cells [69].”
BackgroundBarberio, C., Withers, A. M., Mishra, Y., Couraud, P., Romero, I. A., Weksler, B. B., & Owens, R. M. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1065193 · Cited by 40
“Several neuropathological conditions, including stroke, epilepsy, Parkinson’s and Alzheimer’s disease, are associated with BBB dysfunction (Cai et al., 2018; Modarres et al., 2018).”
BackgroundSanfilippo, C., Castrogiovanni, P., Imbesi, R., Tibullo, D., Volti, G. L., Barbagallo, I. A., Vicario, N., Musumeci, G., & Rosa, M. D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.008 · Cited by 36
Qu, C., Song, H., Shen, J., Xu, L., Li, Y., Qu, C., Li, T., & Zhang, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00461 · Cited by 35
“edema and neuron apoptosis, increase amyloid beta production, and decrease its clearance, and the toxic effect of amyloid beta further aggravates BBB dysfunction, finally leading to cognitive impairment (Cai et al., 2018; Cockerill et al., 2018).”
BackgroundEvaluation of chronic lead effects in the blood brain barrier system by DCE-CT
Gu, H., Territo, P. R., Persohn, S. A., Bedwell, A. A., Eldridge, K., Speedy, R., Chen, Z., Zheng, W., & Du, Y. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126648 · Cited by 36
Cortés, A., Solas, M., Pejenaute, Á., Abellanas, M. A., Garcia-Lacarte, M., Aymerich, M. S., Marqués, J., Ramírez, M. J., & Zalba, G. (2021) · Antioxidants · doi:10.3390/antiox10081311 · Cited by 33
“Functional BBB integrity can be disrupted by neuroinflammation and oxidative stress, associated with many age-related disorders, such as Alzheimer’s disease [9] or Parkinson’s disease [10].”
BackgroundZhu, N., Wei, M., Yuan, L., He, X., Chen, C., Ji, A., & Zhang, G. (2022) · Aging · doi:10.18632/aging.204029 · Cited by 36
“So Aβ and tau may thus accelerate the BBB integrity loss, which probably also cause vascular dysfunction and AD [22].”
BackgroundQin, S.-J., Zeng, Q.-G., Zeng, H.-X., Li, S.-P., Andersson, J., Zhao, B., Oudin, A., Kanninen, K. M., Jalava, P., Jin, N.-X., et al. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.174450 · Cited by 36
Recent Insights into the Neurobiology of Alzheimer’s Disease and Advanced Treatment Strategies
Anitha, K., Singh, M. K., Kohat, K., Varshini, T. S., Chenchula, S., Padmavathi, R., Amerneni, L. S., Vishnu Vardhan, K., Mythili Bai, K., Chavan, M. R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04384-1 · Cited by 42
“[42].”
Ding, X., Hu, Y., Feng, X., Wang, Z., Song, Q., Dai, C., Yang, B., Fu, X., Sun, D., & Fan, C. (2025) · Exploration · doi:10.1002/exp.20230178 · Cited by 36
“Prussian blue-like nanoparticles have good light-to-heat conversion efficiency under near-infrared irradiation (NIR) and may have certain advantages in improving BBB permeability [31– 35].”
Role of astrocytes in sleep deprivation: accomplices, resisters, or bystanders?
Que, M., Li, Y., Wang, X., Zhan, G., Luo, X., & Zhou, Z. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1188306 · Cited by 37
“(A) SD leads to low levels of LRP-1 at the BBB and increased expression of RAGE.”
BackgroundInfluential
Metadata
- Authors
- Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q.
- Affiliations
- Department of Neurology, Chongqing General Hospital, Chongqing, Chongqing, China
- Corresponding author
- Cai, Zhiyou
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-05-30
- Volume
- 63
- Issue
- 4
- Pages
- 1223-1234
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2804234159
- Cited by
- 370
- References
- 133
- Citations by year
- 2026: 31 · 2025: 59 · 2024: 63 · 2023: 69 · 2022: 49 · 2021: 63 · 2020: 25 · 2019: 10 · 2018: 1
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- blood-brain barrier, Alzheimer's disease
- MeSH terms
- Receptor for Advanced Glycation End Products, Alzheimer Disease, Blood-Brain Barrier, Humans, Amyloid beta-Peptides, Low Density Lipoprotein Receptor-Related Protein-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.